Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice

N. Irwin, P.L. McClean, F.P.M. O'Harte, V.A. Gault, Patrick Harriott, P.R. Flatt

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Aims/hypothesis Ablation of gastric inhibitory polypeptide ( GIP) receptor action is reported to protect against obesity and associated metabolic abnormalities. The aim of this study was to use prediabetic ob/ob mice to examine whether 60 days of chemical GIP receptor ablation with (Pro(3)) GIP is able to counter the development of genetic obesity-related diabetes.
Original languageEnglish
Pages (from-to)1532-1540
Number of pages9
JournalDiabetologia
Volume50
Issue number7
DOIs
Publication statusPublished - Jul 2007

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Fingerprint Dive into the research topics of 'Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice'. Together they form a unique fingerprint.

Cite this